source
- Rising costs leave 9 in 10 new medicines unprofitable, IQVIA findsTo achieve a positive return, drugs launched from 2016 to 2020 must generate nearly $12 billion in sales, up from just $1.4 billion for drugs launched in the early 1990s.BioSpace · 1h ago↗ source
- Lilly adds to buyout streak with $1.5B purchase of startup CalytrixLilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neop…BioPharma Dive · 1h ago↗ source
- Aclaris scratches TSLP program from pipeline after flunking phase 2 eczema testA phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.